Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C28H26N2O5 |
| Molecular Weight | 470.5164 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(COC2=CC=C(CO\N=C(/CCC(O)=O)C3=CC=CC=C3)C=C2)N=C(O1)C4=CC=CC=C4
InChI
InChIKey=ULVDFHLHKNJICZ-QCWLDUFUSA-N
InChI=1S/C28H26N2O5/c1-20-26(29-28(35-20)23-10-6-3-7-11-23)19-33-24-14-12-21(13-15-24)18-34-30-25(16-17-27(31)32)22-8-4-2-5-9-22/h2-15H,16-19H2,1H3,(H,31,32)/b30-25+
| Molecular Formula | C28H26N2O5 |
| Molecular Weight | 470.5164 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Imiglitazar (also known as TAK-559) is a dual peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist patented by Japanese pharmaceutical company Takeda Chemical Industries for the prevention or treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance, and impaired glucose tolerance. Imiglitazar shows potent hypoglycemic and hypolipidemic activity and has been studied in clinical trials in treating subjects receiving a stable dose of insulin to control type 2 diabetes mellitus. Unfortunately, Imiglitazar shows hepatotoxicity and has never been marketed.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00762190
TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:16:49 GMT 2025
by
admin
on
Wed Apr 02 09:16:49 GMT 2025
|
| Record UNII |
7244710F59
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98233
Created by
admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000034214
Created by
admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
|
PRIMARY | |||
|
CHEMBL592054
Created by
admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
|
PRIMARY | |||
|
DTXSID00870280
Created by
admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
|
PRIMARY | |||
|
DB12511
Created by
admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
|
PRIMARY | |||
|
8460
Created by
admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
|
PRIMARY | |||
|
9890879
Created by
admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
|
PRIMARY | |||
|
7244710F59
Created by
admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
|
PRIMARY | |||
|
C83791
Created by
admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
|
PRIMARY | |||
|
250601-04-8
Created by
admin on Wed Apr 02 09:16:49 GMT 2025 , Edited by admin on Wed Apr 02 09:16:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
||
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|